Table 4.

Performance of renal arrest biomarkers for predicting septic AKI progression in single or combination with clinical risk factors

Outcomes	AUC	95%CI
AKI progression
u[TIMP-2]*[IGFBP7]	0.745	0.667 to 0.823
u[TIMP-2]*[IGFBP7] + APACHE II	0.779	0.706 to 0.852
u[TIMP-2]*[IGFBP7]] + SOFA	0.752	0.675 to 0.829
u[TIMP-2]*[IGFBP7] + SCr at time of AKI diagnosis	0.752	0.675 to 0.829
u[TIMP-2]*[IGFBP7] + SCys-C at time of AKI diagnosis	0.754	0.677 to 0.831
u[TIMP-2]*[IGFBP7] + Ma	0.797	0.726 to 0.867
u[TIMP-2]*[IGFBP7] + uKIM-1 + M	0.806	0.738 to 0.874
AKI progression with death
u[TIMP-2]*[IGFBP7]	0.777	0.700 to 0.854
u[TIMP-2]*[IGFBP7] + APACHE II	0.828	0.760 to 0.897
u[TIMP-2]*[IGFBP7]] + SOFA	0.797	0.723 to 0.871
u[TIMP-2]*[IGFBP7] + SCr at time of AKI diagnosis	0.784	0.708 to 0.860
u[TIMP-2]*[IGFBP7] + SCys-C at time of AKI diagnosis	0.785	0.708 to 0.861
u[TIMP-2]*[IGFBP7] + M	0.845	0.780 to 0.910
u[TIMP-2]*[IGFBP7] + uKIM-1 + M	0.846	0.780 to 0.910

AKI progression is defined as worsening of AKI stage

^a M, clinical risk factor model. The clinical risk factor model for predicting AKI progression are comprised of age, gender, APACHE II, SCr at time of diagnosis, uACR at time of AKI diagnosis (AUC 0.746, 95% CI 0.668 to 0.823); The clinical risk model for predicting AKI progression with death are comprised of age, gender, APACHE II, SCr at time of diagnosis, uACR at time of AKI diagnosis (AUC 0.779, 95% CI 0.702 to 0.855)

Abbreviation: AUC area under the receiver-operating characteristic curve, CI confidence interval; u[TIMP-2]*[IGFBP7], urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7; APACHE II, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SCr, serum creatinine; SCys-C, serum cystatin C; uKIM-1, urinary kidney injury moleculer-1